

| | | | | | |
|---|---|----|---|--------------------------|------------------------|
| PTO/SB/08A SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 09/857,994 |
| | | | | Filing Date | October 5, 2001 |
| | | | | Confirmation Number | 4028 |
| | | | | First Named Inventor | John P. McKearn et al. |
| | | | | Group Art Unit | 1617 |
| | | | | Examiner Name | San-ming R. Hui |
| Sheet | 1 | of | 2 | Attorney Docket No. | PHA 2005 (3167/6Z/US) |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
|--------------------|-----------------------|----------------------|--------------------------------------|---|---|
| | | Number | Kind Code ² (if known) | | |
| | 282. | 6,077,850 | | Carter et al. | 06-20-2000 |
| | 283. | 6,087,392 | | Reiter | 07-11-2000 |
| | 284. | 6,110,964 | | Robinson | 08-29-2000 |
| | 285. | 6,114,361 | | Robinson et al. | 09-05-2000 |
| | 286. | 6,156,798 | | Reiter | 12-05-2000 |
| | 287. | 6,214,870 | B1 | McClure et al. | 04-10-2001 |
| | 288. | 6,277,878 | B1 | Nakao et al. | 08-21-2001 |
| | 289. | 6,294,558 | B1 | Ando et al. | 09-25-2001 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | T ⁶ |
|--------------------|-----------------------|-------------------------|---------------------|--------------------------------------|---|---|----------------|
| | | Office | Number ⁴ | Kind Code ² (if known) | | | |
| | 290. | EP | 1 081 137 | A1 | Pfizer Products Inc. | 03-07-2001 | |
| | 291. | EP | 1 088 550 | A1 | Pfizer Products Inc. | 04-04-2001 | |
| | 292. | EP | 1 104 759 | A1 | Pfizer Products Inc. | 06-06-2001 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

| | | | | | |
|---|---|----|---|--------------------------|------------------------|
| DTC/SB/08A SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 09/857,994 |
| | | | | Filing Date | October 5, 2001 |
| | | | | Confirmation Number | 4028 |
| | | | | First Named Inventor | John P. McKearn et al. |
| | | | | Group Art Unit | 1617 |
| | | | | Examiner Name | San-ming R. Hui |
| Sheet | 2 | of | 2 | Attorney Docket No. | PHA 2005 (3167/6Z/US) |

| | | | | | | | |
|--|------|----|-----------|----|----------------------|------------|--|
| | 293. | EP | 1 104 760 | A1 | Pfizer Products Inc. | 06-06-2001 | |
| | 294. | EP | 1 134 215 | A1 | Pfizer Products Inc. | 09-19-2001 | |
| | 295. | EP | 1 138 680 | A1 | Pfizer Products Inc. | 10-04-2001 | |
| | 296. | WO | 97/48685 | A1 | Glaxo Group Limited | 12-24-1997 | |
| | 297. | WO | 98/03516 | A1 | Pfizer Inc. | 01-29-1998 | |
| | 298. | WO | 98/30566 | A1 | Pfizer Inc. | 07-16-1998 | |
| | 299. | WO | 98/47890 | A1 | G.D. Searle & Co. | 10-29-1998 | |
| | 300. | WO | 00/09485 | A1 | Pfizer Products Inc. | 02-24-2000 | |
| | 301. | WO | 00/09492 | A1 | Pfizer Products Inc. | 02-24-2000 | |
| | 302. | WO | 00/73294 | A2 | Pfizer Products Inc. | 12-07-2000 | |
| | 303. | WO | 01/12611 | A1 | Pfizer Products Inc. | 02-22-2001 | |
| | 304. | WO | 01/40216 | A1 | Pfizer Products Inc. | 06-07-2001 | |

OTHER ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

| | | | | |
|---|---|----|--|--|
| PTO/SB/08A | | | Complete if Known Application Number 09/857,994 Filing Date October 5, 2001 Confirmation Number Unknown First Named Inventor John P. McKearn et al. Group Art Unit 1646 Examiner Name Unknown | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | |
| Sheet | 1 | of | 13 | Attorney Docket No. PHA 4295 (3167/6Z) |

RECEIVED
 AUG 20 2003
 TECH CENTER 1601/1600

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|----------------------|--|--|--|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
| | | Number | Kind Code ² (if known) | | |
| | 1. | 4,100,274 | | Dutta et al. | 07-11-1978 |
| | 2. | 4,105,681 | | Bollag et al. | 08-08-1978 |
| | 3. | 4,140,707 | | Cleare et al. | 02-20-1979 |
| | 4. | 4,215,215 | | Bollag et al. | 07-29-1980 |
| | 5. | 4,310,666 | | Zee-Cheng et al. | 01-12-1982 |
| | 6. | 4,472,382 | | Labrie et al. | 09-18-1984 |
| | 7. | 4,596,797 | | Schweikert et al. | 06-24-1986 |
| | 8. | 5,250,683 | | Holton et al. | 10-05-1993 |
| | 9. | 5,254,703 | | Holton | 10-19-1993 |
| | 10. | 5,272,171 | | Ueda et al. | 12-21-1993 |
| | 11. | 5,319,112 | | Kingston et al. | 06-07-1994 |
| | 12. | 5,344,991 | | Reitz et al. | 09-06-1994 |
| | 13. | 5,455,270 | | Kaplan et al. | 10-03-1995 |
| | 14. | 5,633,016 | | Johnson | 05-27-1997 |
| | 15. | 5,686,419 | | Powers et al. | 11-11-1997 |
| | 16. | 5,696,131 | | Baguley et al. | 12-09-1997 |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

| | | | | | |
|--|---|----|--------------------------|------------------------|--------------------|
| PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Complete if Known | | |
| | | | Application Number | 09/857,994 | |
| | | | Filing Date | October 5, 2001 | |
| | | | Confirmation Number | Unknown | |
| | | | First Named Inventor | John P. McKearn et al. | |
| | | | Group Art Unit | 1646 | |
| | | | Examiner Name | Unknown | |
| Sheet | 1 | of | 13 | Attorney Docket No. | PHA 4295 (3167/6Z) |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|----------------------|--------------------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
| | | Number | Kind Code ² (if known) | | |
| | 1. | 4,100,274 | | Dutta et al. | 07-11-1978 |
| | 2. | 4,105,681 | | Bollag et al. | 08-08-1978 |
| | 3. | 4,140,707 | | Cleare et al. | 02-20-1979 |
| | 4. | 4,215,215 | | Bollag et al. | 07-29-1980 |
| | 5. | 4,310,666 | | Zee-Cheng et al. | 01-12-1982 |
| | 6. | 4,472,382 | | Labrie et al. | 09-18-1984 |
| | 7. | 4,596,797 | | Schweikert et al. | 06-24-1986 |
| | 8. | 5,250,683 | | Holton et al. | 10-05-1993 |
| | 9. | 5,254,703 | | Holton | 10-19-1993 |
| | 10. | 5,272,171 | | Ueda et al. | 12-21-1993 |
| | 11. | 5,319,112 | | Kingston et al. | 06-07-1994 |
| | 12. | 5,344,991 | | Reitz et al. | 09-06-1994 |
| | 13. | 5,455,270 | | Kaplan et al. | 10-03-1995 |
| | 14. | 5,633,016 | | Johnson | 05-27-1997 |
| | 15. | 5,686,419 | | Powers et al. | 11-11-1997 |
| | 16. | 5,696,131 | | Baguley et al. | 12-09-1997 |
| Examiner Signature | | | | Date Considered | |


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

| | | | | |
|---|--|--|--------------------------|------------------------|
| PTO/SB/08A | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 09/857,994 |
| | | | Filing Date | October 5, 2001 |
| | | | Confirmation Number | Unknown |
| | | | First Named Inventor | John P. McKearn et al. |
| | | | Group Art Unit | 1646 |
| | | | Examiner Name | Unknown |
| | | | Attorney Docket No. | PHA 4295 (3167/6Z) |
| Sheet 2 of 13 | | | | |

RECEIVED
 AUG 20 2003
 TECH CENTER 1600



| | | | |
|-----|-----------|---------------|------------|
| 17. | 5,733,909 | Black et al. | 03-31-1998 |
| 18. | 5,767,142 | LaVoie et al. | 06-16-1998 |
| 19. | 5,824,699 | Kreft et al. | 10-20-1998 |
| 20. | 5,837,696 | Golub et al. | 11-17-1998 |
| 21. | 5,869,524 | Failli | 02-09-1999 |
| 22. | 5,952,381 | Chen et al. | 09-14-1999 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | T ⁶ |
|--------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|----------------|
| | | Office | Number ⁴ | Kind Code ² (if known) | | | |
| | 23. | DE | 195 48 798 | A1 | Dr. Karl Thomae GmbH | 07-03-1997 | A |
| | 24. | DE | 196 13 933 | A1 | Merck Patent GmbH | 10-09-1997 | A |
| | 25. | DE | 196 26 701 | A1 | Hoechst AG | 01-08-1998 | A |
| | 26. | EP | 0 010 458 | A1 | ANVAR | 04-30-1980 | A |
| | 27. | EP | 0 054 168 | A1 | Klinge Pharma GmbH & Co. | 06-23-1982 | A |
| | 28. | EP | 0 095 875 | A2 | Farmos Group Ltd. | 12-07-1983 | |
| | 29. | EP | 0 165 904 | A2 | Ciba-Geigy AG | 12-27-1985 | A |
| | 30. | EP | 0 199 636 | A1 | C.I.R.D. | 10-29-1986 | A |
| | 31. | EP | 0 236 940 | B1 | Ciba-Geigy AG | 09-16-1987 | |
| | 32. | EP | 0 260 744 | B1 | Janssen Pharmaceutica N.V. | 03-23-1988 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete If Known

Application Number 09/857,994
 Filing Date October 5, 2000
 Confirmation Number Unknown
 First Named Inventor John P. McKearn et al.
 Group Art Unit 1646
 Examiner Name Unknown

Sheet

3

of

13

Attorney Docket No.

PHA 4295 (3167/6Z)

| | | | | | | |
|-----|----|-----------|----|--|------------|---|
| 33. | EP | 0 299 402 | A2 | ASTA Pharma Aktiengesellschaft | 01-18-1989 | A |
| 34. | EP | 0 331 983 | A2 | F. Hoffmann-La Roche AG | 09-13-1989 | A |
| 35. | EP | 0 402 232 | A1 | Rhone-Poulenc Sante | 12-12-1990 | A |
| 36. | EP | 0 532 156 | A1 | Matsuno et al. | 03-17-1993 | |
| 37. | EP | 0 579 915 | A1 | F. Hoffmann-La Roche AG | 01-26-1994 | A |
| 38. | EP | 0 702 962 | A2 | Eli Lilly and Company | 03-27-1996 | |
| 39. | EP | 0 703 239 | A1 | Hoechst Aktiengesellschaft | 03-27-1996 | A |
| 40. | EP | 0 716 086 | A1 | Boehringer Mannheim GMBH | 06-12-1996 | |
| 41. | EP | 0 743 070 | A2 | Trnka Mudr et al. | 11-20-1996 | A |
| 42. | EP | 0 758 649 | A1 | Kureha Chemical Industry Co., Ltd. | 02-19-1997 | |
| 43. | EP | 0 882 734 | A2 | F. Hoffman-La Roche AG | 12-09-1998 | |
| 44. | EP | 0 921 119 | A1 | ADIR Et Compagnie | 06-09-1999 | A |
| 45. | GB | 2 282 598 | A | Merck & Co., Inc. | 04-12-1995 | |
| 46. | WO | 87/07609 | A1 | Taiho Pharmaceutical Co., Ltd. | 12-17-1987 | A |
| 47. | WO | 93/11145 | A1 | Banyu Pharmaceutical Co., Ltd. | 06-10-1993 | |
| 48. | WO | 93/18652 | A1 | Merck & Co. | 09-30-1993 | |
| 49. | WO | 93/20229 | A1 | Genentech, Inc. | 10-14-1993 | |
| 50. | WO | 94/02466 | A1 | The Du Pont Merck Pharmaceutical Company | 02-03-1994 | |
| 51. | WO | 94/12169 | A1 | Merck & Co., Inc. | 06-09-1994 | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Complete if Known

Application Number 09/857,994
 Filing Date October 5, 2001
 Confirmation Number Unknown
 First Named Inventor John P. McKearn et al.
 Group Art Unit 1646
 Examiner Name Unknown

Sheet 4 of 13 Attorney Docket No. PHA 4295 (3167/6Z)

RECEIVED
 AUG 2 3 2003
 TECH CENTER 1600/12900

| | | | | | | |
|-----|----|----------|----|---|------------|--|
| 52. | WO | 94/13635 | A1 | Merck Frosst Canada Inc. | 06-23-1994 | |
| 53. | WO | 94/20480 | A1 | Merck Frosst Canada Inc. | 09-15-1994 | |
| 54. | WO | 94/21612 | A1 | Otsuka Pharmaceutical Co., Ltd. | 09-29-1994 | |
| 55. | WO | 94/25431 | A1 | The Wellcome Foundation Limited | 11-10-1994 | |
| 56. | WO | 94/25466 | A1 | Glaxo, Inc. | 11-10-1994 | |
| 57. | WO | 94/26731 | A1 | Merck Frosst Canada Inc. | 11-24-1994 | |
| 58. | WO | 94/27980 | A1 | G.D. Searle & Co. | 12-08-1994 | |
| 59. | WO | 95/02603 | A2 | Pharmacia S.P.A. | 01-26-1995 | |
| 60. | WO | 95/08327 | A1 | The Government of the United States of America | 03-30-1995 | |
| 61. | WO | 95/11883 | A1 | G.D. Searle & Co. | 05-04-1995 | |
| 62. | WO | 95/12606 | A1 | The Wellcome Foundation Limited | 05-11-1995 | |
| 63. | WO | 95/15316 | A1 | G.D. Searle & Co. | 06-08-1995 | |
| 64. | WO | 95/24199 | A2 | Cell Therapeutics, Inc. | 09-14-1995 | |
| 65. | WO | 95/28426 | A2 | La Jolla Cancer Research Foundation | 10-26-1995 | |
| 66. | WO | 95/30652 | A1 | G.D. Searle & Co. | 11-16-1995 | |
| 67. | WO | 95/30656 | A1 | G.D. Searle & Co. | 11-16-1995 | |
| 68. | WO | 96/00574 | A1 | Smithkline Beecham Corporation | 01-11-1996 | |
| 69. | WO | 96/00581 | A1 | Texas Biotechnology Corporation | 01-11-1996 | |
| 70. | WO | 96/01653 | A1 | Board of Regents, The University of Texas System et al. | 01-25-1996 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 09/857,994
 Filing Date October 5, 2001
 Confirmation Number Unknown
 First Named Inventor John P. McKearn et al.
 Group Art Unit 1646
 Examiner Name Unknown

(Use as many sheets as necessary)

Sheet 5 of 13 Attorney Docket No. PHA 4295 (3167/6Z)

| | | | | | |
|-----|----|----------|----|---|------------|
| 71. | WO | 96/03387 | A1 | G.D. Searle & Co. | 02-08-1996 |
| 72. | WO | 96/03392 | A1 | G.D. Searle & Co. | 02-08-1996 |
| 73. | WO | 96/06840 | A1 | Merck Frosst Canada Inc. | 03-07-1996 |
| 74. | WO | 96/14745 | A1 | The Regents of the University of California | 05-23-1996 |
| 75. | WO | 96/21667 | A1 | Merck Frosst Canada Inc. | 07-18-1996 |
| 76. | WO | 96/33988 | A1 | Wisconsin Alumni Research Foundation | 10-31-1996 |
| 77. | WO | 96/35774 | A2 | The Children's Medical Center Corporation | 11-14-1996 |
| 78. | WO | 96/36335 | A1 | Pharmacia S.P.A. | 11-21-1996 |
| 79. | WO | 96/36612 | A1 | Rutgers, The State University of New Jersey | 11-21-1996 |
| 80. | WO | 96/36622 | A1 | Indena S.P.A. | 11-21-1996 |
| 81. | WO | 96/36623 | A1 | Merck Frosst Canada Inc. | 11-21-1996 |
| 82. | WO | 96/37489 | A1 | Merck Frosst Canada Inc. | 11-28-1996 |
| 83. | WO | 97/08145 | A1 | G.D. Searle & Co. | 03-06-1997 |
| 84. | WO | 97/11718 | A1 | The Victoria University of Manchester | 04-03-1997 |
| 85. | WO | 97/15666 | A1 | The Children's Medical Center Corporation | 05-01-1997 |
| 86. | WO | 97/15676 | A2 | Abbott Laboratories | 05-01-1997 |
| 87. | WO | 97/19954 | A1 | Asta Medica Aktiengesellschaft | 06-05-1997 |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED
 AUG 2 8 2003
 TECH CENTER 1600/2900

| | | | | | |
|---|---|----|----|--------------------------|--------------------------|
| PTO/SB/08A | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/857,994 |
| | | | | Filing Date | October 5, 2000 |
| | | | | Confirmation Number | Unknown |
| | | | | First Named Inventor | John P. McKearney et al. |
| | | | | Group Art Unit | 1646 |
| | | | | Examiner Name | Unknown |
| Sheet | 6 | of | 13 | Attorney Docket No. | PHA 4295 (3167/6Z) |

RECEIVED
 AUG 2 3 2001
 TECH CENTER 160016800

OIPE (JC18)
 AUG 15 2003
 RECEIVED & PROCESSED

| | | | | | | | |
|--|------|----|----------|----|--|------------|---|
| | 88. | WO | 97/20835 | A1 | Harbor Branch Oceanographic Institution, Inc. | 06-12-1997 | |
| | 89. | WO | 97/23451 | A1 | Merck Patent Gesellschaft Mit Beschränkter Haftung | 07-03-1997 | A |
| | 90. | WO | 97/23480 | A1 | The Du Pont Merck Pharmaceutical Company | 07-03-1997 | |
| | 91. | WO | 97/24116 | A2 | Allergan | 07-10-1997 | |
| | 92. | WO | 97/29106 | A1 | Rutgers, The State University of New Jersey | 08-14-1997 | |
| | 93. | WO | 97/31936 | A2 | Wisconsin Alumni Research Foundation | 09-04-1997 | |
| | 94. | WO | 97/33887 | A1 | The Du Pont Merck Pharmaceutical Company | 09-18-1997 | |
| | 95. | WO | 97/34608 | A1 | Mayo Foundation for Medical Education and Research | 09-25-1997 | |
| | 96. | WO | 97/36497 | A2 | Mars, Incorporated | 10-09-1997 | |
| | 97. | WO | 97/36860 | A1 | G.D. Searle & Co. | 10-09-1997 | |
| | 98. | WO | 97/36863 | A1 | Merck Frosst Canada Inc. | 10-09-1997 | |
| | 99. | WO | 97/37658 | A1 | Boehringer Mannheim Italia S.P.A. | 10-16-1997 | |
| | 100. | WO | 97/41844 | A1 | Alcon Laboratories, Inc. | 11-13-1997 | |
| | 101. | WO | 97/47296 | A2 | Mount Sinai Hospital Corporation | 12-18-1997 | |
| | 102. | WO | 97/49704 | A1 | Janssen Pharmaceutica N.V. | 12-31-1997 | |
| | 103. | WO | 98/03484 | A1 | Merck Frosst Canada Inc. | 01-29-1998 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

| | | | | | |
|---|---|----|--------------------------|------------------------|--------------------|
| PTO/SB/08A | | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 09/857,994 | |
| | | | Filing Date | October 5, 2000 | |
| | | | Confirmation Number | Unknown | |
| | | | First Named Inventor | John P. McKearn et al. | |
| | | | Group Art Unit | 1646 | |
| | | | Examiner Name | Unknown | |
| Sheet | 7 | of | 13 | Attorney Docket No. | PHA 4295 (3167/6Z) |



RECEIVED
 AUG 2 3 2000
 TECH CENTER 1600

| | | | | | | | |
|--|------|----|----------|----|---|------------|--|
| | 104. | WO | 98/07432 | A1 | American Home Products Corporation | 02-26-1998 | |
| | 105. | WO | 98/07433 | A1 | Bristol-Myers Squibb Company | 02-26-1998 | |
| | 106. | WO | 98/12181 | A1 | Rutgers, The State University of New Jersey | 03-26-1998 | |
| | 107. | WO | 98/13350 | A1 | Zeneca Limited | 04-02-1998 | |
| | 108. | WO | 98/14188 | A1 | Ilex Oncology Inc. | 04-09-1998 | |
| | 109. | WO | 98/16227 | A1 | G.D. Searle & Co. | 04-23-1998 | |
| | 110. | WO | 98/22101 | A2 | G.D. Searle & Co. | 05-28-1998 | |
| | 111. | WO | 98/25603 | A1 | Ilex Oncology, Inc. | 06-18-1998 | |
| | 112. | WO | 98/25896 | A1 | G.D. Searle & Co. | 06-18-1998 | |
| | 113. | WO | 98/40104 | A2 | Yale University et al. | 09-17-1998 | |
| | 114. | WO | 98/45294 | A1 | Astra Pharmaceuticals Ltd. | 10-15-1998 | |
| | 115. | WO | 99/01131 | A1 | Smithkline Beecham Corporation | 01-14-1999 | |
| | 116. | WO | 99/05104 | A1 | Pfizer Pharmaceuticals Inc. | 02-04-1999 | |
| | 117. | WO | 99/10331 | A1 | Abbott Laboratories | 03-04-1999 | |
| | 118. | WO | 99/12930 | A1 | Glaxo Group Limited | 03-18-1999 | |
| | 119. | WO | 99/14194 | A1 | Merck Frosst Canada Inc. | 03-25-1999 | |
| | 120. | WO | 99/14205 | A1 | Almirall Prodesfarma S.A. | 03-25-1999 | |
| | 121. | WO | 99/21583 | A1 | Warner-Lambert Company | 05-06-1999 | |
| | 122. | WO | 99/23087 | A1 | Merck Frosst Canada & Co. | 05-14-1999 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

| | | | | | |
|---|---|----|--------------------------|--------------------------|--------------------|
| PTO/SB/08A | | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 09/857,994 | |
| | | | Filing Date | October 5, 2000 | |
| | | | Confirmation Number | Unknown | |
| | | | First Named Inventor | John P. McKearney et al. | |
| | | | Group Art Unit | 1646 | |
| | | | Examiner Name | Unknown | |
| Sheet | 8 | of | 13 | Attorney Docket No. | PHA 4295 (3167/6Z) |

RECEIVED
 AUG 20 2003
 TECH CENTER 16002500

| | | | | | | | |
|--|------|----|----------|----|---|------------|--|
| | 123. | WO | 99/31067 | A1 | Rutgers, The State University of New Jersey | 06-24-1999 | |
| | 124. | WO | 99/41241 | A1 | Rutgers, The State University of New Jersey | 08-19-1999 | |

OTHER ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-Issue number(s), publisher, city and/or country where published. | T* |
|--------------------|-----------------------|--|----|
| | 125. | BARNI, S., et al., Clinical Efficacy of the Aromatase Inhibitor Anastrozole in Relation to Prolactin Secretion in Heavily Pretreated Metastatic Breast Cancer, Tumouri, Jan.-Feb. 1998, pp. 45-47, Vol. 84(1) | |
| | 126. | BENSON, J.R., et al., Tamoxifen, Biologic Therapy of Cancer: Principles and Practice, 1997, pp. 817-828, Vol. One, Ch. 29, J.F. Holland et al. (Eds.), Baltimore, MD | |
| | 127. | BREMBECK, F.H., et al., A Phase II Pilot Trial of 13-cis Retinoic Acid and Interferon- α in UICC Stage III/IV Pancreatic Cancer, Gastroenterology Oncology, April 1998, Abstract G2329, Vol. 114, No. 4, Pt. 2, A569 | |
| | 128. | BREMBECK, F.H., et al., A Phase II Trial of 13-cis Retinoic Acid and Interferon- α in Patients with Advanced Pancreatic Carcinoma, Cancer, 1998, pp. 2317-2323, Vol. 83, No. 11 | |
| | 129. | BROOKS, P.C., et al., Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels, Cell, Dec. 30, 1994, pp. 1157-1164, Vol. 79 | |
| | 130. | CAO, Y., et al., Kringle Domains of Human Angiostatin, The Journal of Biological Chemistry, Nov. 15, 1996, pp. 29461-29467, Vol. 271, No. 46 | |
| | 131. | DONG, Z, et al., Macrophage-Derived Metalloelastase is Responsible for the Generation of Angiostatin in Lewis Lung Carcinoma, Cell, Mar. 21, 1997, pp. 801-810, Vol. 88 | |
| | 132. | DRUMMOND, A.H., et al., Preclinical and Clinical Studies of MMP Inhibitors in Cancer, Annals of the New York Academy of Science, June 1999, pp. 228-235, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

| | | | | | |
|---|---|----|--------------------------|------------------------|--------------------|
| PTO/SB/08A | | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 09/857,994 | |
| | | | Filing Date | October 5, 2001 | |
| | | | Confirmation Number | Unknown | |
| | | | First Named Inventor | John P. McKeane et al. | |
| | | | Group Art Unit | 1646 | |
| | | | Examiner Name | Unknown | |
| Sheet | 9 | of | 13 | Attorney Docket No. | PHA 4295 (3167/6Z) |

| | | | |
|--|------|---|--|
| | 133. | DURANDO, A., et al., Combination chemotherapy with paclitaxel (T) and epirubicin (E) for metastatic breast cancer (MBC): A phase I-II study, European Journal of Cancer, Sept. 30, 1998, pp. S12-13, Abstract 41 | |
| | 134. | FAN, T.-P.D., et al., Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy, Trends Pharmacol.Sci. Feb. 1995, pp. 57-66, Vol. 16 | |
| | 135. | FISHER, J.E., et al., Inhibition of Osteoclastic Bone Resorption In Vivo by Echistatin, An, "Arginyl-Glycyl-Aspartyl" (RGD)-Containing Protein, Endocrinology, 1993, pp. 1411-1413, Vol. 132, No. 3 | |
| | 136. | FORMENTI, C., et al., Concurrent paclitaxel and radiation in locally advanced breast cancer, European Journal of Cancer, Sept. 30, 1998, p. S12, Abstract 39 | |
| | 137. | GALARDY, R.E., et al., Inhibition of Angiogenesis by the Matrix Metalloprotease Inhibitor N-[2R-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide, Cancer Research, Sept. 1, 1994, pp. 4715-4718, Vol. 54 | |
| | 138. | GIANNIS, A., et al., Integrin Antagonists and Other Low Molecular Weight Compounds as Inhibitors of Angiogenesis: New Drugs in Cancer Therapy, Angew. Chem. Int. Ed. Engl., 1997, pp 588-590, Vol. 36, No. 6 | |
| | 139. | GUTTERMAN, J.U., Cytokine Therapeutics: Lessons from interferon α , Proc. Natl. Acad. Sci., USA, Feb. 1994, pp. 1198-1205, Vol. 91 | |
| | 140. | HANDSCHUMACHER, R.E., et al., Purine and Pyrimidine Antimetabolites, Chemotherapeutic Agents, pp. 712-732, Ch. XV1-2, 3rd Edition, Edited by J. Holland, et al., Lea and Febigol, publishers | |
| | 141. | IHDE, D.C., M.D., Current Status of Therapy for Small Cell Carcinoma of the Lung, Cancer, Dec. 1, 1984 Supplement, pp. 2722-2728, Vol. 54 | |
| | 142. | International Search Report for Application No. PCT/US99/30670, dated September 5, 2000 | |
| | 143. | JAYSON, G.C., ET AL., A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer, British Journal of Cancer, 1998, pp. 366-369, Vol. 78(3) | |
| | 144. | JOSS, R.A., et al., New agents in non-small cell lung cancer, Cancer Treatment Reviews, 1984, pp. 205-236, Vol.11 | |



| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| PTO/SB/08A | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 09/857,994 |
| | | | | Filing Date | October 5, 2000 |
| | | | | Confirmation Number | Unknown |
| | | | | First Named Inventor | John P. McKearn et al. |
| | | | | Group Art Unit | 1646 |
| | | | | Examiner Name | Unknown |
| Sheet | 10 | of | 13 | Attorney Docket No. | PHA 4295 (3167/6Z) |



| | |
|------|---|
| 145. | KROWN, S.E., The Role of Interferon in the Therapy of Epidemic Kaposi's Sarcoma, Seminars in Oncology, June, 1987, pp.27-33, Vol. 14, No. 2, Suppl. 3 |
| 146. | LINGEN, M.W., et al., Retinoic Acid and Interferon α Act Synergistically as Antiangiogenic and Antitumor Agents against Human Head and Neck Squamous Cell Carcinoma, Cancer Research, Dec. 1, 1998, pp. 5551-5558, Vol. 58 |
| 147. | LODE, H.N., et al., Synergy between an antiangiogenic integrin α , antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases, Proc. Nat. Acad. Sci. USA., Feb. 1999, pp. 1591-1596, Vol. 96 |
| 148. | LOKESHWAR, B.L, MMP Inhibition in Prostate Cancer, Annals of the New York Academy of Science, June 1999, pp. 271-289, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.) |
| 149. | MACKEAN, M.J., et al., A feasibility study of roquimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma, British Journal of Cancer, 1998, pp. 1620-1623, Vol. 78(12) |
| 150. | MAIONE, T.E., et al., Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides, Science, Jan. 5, 1990, pp. 77-79, Vol. 247 |
| 151. | MAJEWSKI, S., et al., Synergistic Anticancer Action of Retinoids, Vitamin D3 and Cytokines (Interferons and Interleukin-12) as Related to the Antiangiogenic and Antiproliferative Effects, J.Invest.Dermatol., April 1997, Abstract 202, Vol. 108, No. 4 |
| 152. | MONTGOMERY, A.M.P., et al., Integrin $\alpha_v\beta_3$ rescues melanoma cells from apoptosis in three-dimensional dermal collagen, Proc. Natl. Acad. Sci. USA, Sept. 1994, pp. 8856-8860, Vol. 91 |
| 153. | MOON, R.C., et al., N-(4-Hydroxyphenyl)retinamide, A New Retinoid for Prevention of Breast Cancer in the Rat, Cancer Research, April 1979, pp. 1339-1346, Vol. 39 |
| 154. | MÜLLER, H., Antio-genesis-inhibition and intra-arterial chemotherapy - A new modality treatment for advanced and metastatic pancreatic carcinoma, Eur.J.Cancer 33, 1997, Abstract 215, p. S50, Suppl. 8 |
| 155. | NAITO, K., et al., Inhibition of Growth of Human Tumor Cells in Nude Mice by a Metalloproteinase Inhibitor, Int. J. Cancer, 1994, pp. 730-735, Vol 58 |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

| | | | | |
|--|--|--|--------------------------|-----------------|
| PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Complete if Known | |
| | | | Application Number | 09/857,994 |
| | | | Filing Date | October 5, 2000 |
| | | | Confirmation Number | Unknown |
| | | | First Named Inventor | John P. McKearn |
| | | | Group Art Unit | 1646 |
| | | | Examiner Name | Unknown |
| Sheet 11 of 13 | Attorney Docket No. PHA 4295 (3167/6Z) | | | |

RECEIVED
 AUG 2 2 2003
 TECH CENTER 1600 18300

| | |
|------|---|
| 156. | NERI, A., et al., Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor, AG3340, in single agent and combination therapy against B16-F10 melanoma tumors developing in the lung after IV-tail vein implantation in C57BL/6 mice, Proceedings of the American Association for Cancer Research, Mar. 1998, p. 302, Abstract 2060, Vol. 39 |
| 157. | O'REILLY, M.S., et al., Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth, Cell, Jan. 24, 1997, pp. 277-285, Vol. 88 |
| 158. | OSAKI, A., et al., A combination therapy with mitomycin-C, etoposide, doxorubicin and medroxyprogesterone acetate as second-line therapy for advanced breast cancer, European Journal of Cancer, Sept. 30, 1998, p. S16, Abstract 56 |
| 159. | PFAFF, M., et al., Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by α IIb β 3, α V β 3, and α 5 β 1 Integrins, The Journal of Biological Chemistry, Aug. 12, 1994, pp. 20233-20238, Vol. 269, No. 32 |
| 160. | POWLES, T.J., II.1 Tamoxifen's Oestrogen-like Effects in a Breast Cancer Chemoprevention Trial, European Journal of Cancer, 1998, pp. S17-S18, Vol. 34, Suppl. 4, printed in Great Britain |
| 161. | RAVAUD, A., et al., Subcutaneous Interleukin-2, Interferon Alfa-2a, and Continuous Infusion of Fluorouracil in Metastatic Renal Cell Carcinoma: A Multicenter Phase II Trial, Journal of Clinical Oncology, Aug. 1998, pp. 2728, 2732, Vol. 16, No. 8 |
| 162. | ROSENBERG, S.A., et al., Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b, Journal of Clinical Oncology, Mar. 1999, pp. 968-975, Vol. 17, No. 3 |
| 163. | RYAN, C.W., et al., A Phase II Trial of Outpatient Subcutaneous GM-CSF, Interleukin-2, and Interferon-Alpha Plus Oral cis-Retinoic Acid in Patients with Metastatic Renal Cell Cancer, J.Invest.Med., 1998, p. 274A, Vol. 46, No. 7 |
| 164. | SCHACHER, J., et al., A Sequential Four-drug Chemotherapy and Biotherapy with Interferon Alpha and GM-CSF - An Innovative Protocol for the Treatment of Metastatic Melanoma, Cancer Biotherapy & Radiopharmaceuticals, 1998, pp. 155-164, Vol. 13, No. 3 |
| 165. | SEFTOR, R.E.B., et al., Role of the α β γ integrin in human melanoma cell invasion, Proc. Natl. Acad. Sci. USA, Mar. 1992, pp. 1557-1561, Vol. 89 |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

| | |
|----------------------|--------------------|
| Application Number | 09/857,994 |
| Filing Date | October 5, 2001 |
| Confirmation Number | Unknown |
| First Named Inventor | John P. McKearn et |
| Group Art Unit | 1646 |
| Examiner Name | Unknown |
| Attorney Docket No. | PHA 4295 (3167/6Z) |

12

of

13

RECEIVED
AUG 20 2003
TECH CENTER 16012898

| | | |
|------|---|---|
| 166. | SHALINSKY, et al., Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials, Annals of the New York Academy of Science, June 1999, pp. 236-270, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.) | |
| 167. | SILBER, R., et al., DNA Topoisomerase I Inhibitors, Purine and Pyrimidine Antimetabolites, Chemotherapeutic Agents, pp. 779-782, Ch. XV1-7, 3rd Edition, Edited by J. Holland, et al., Lea and Febigol, publishers | |
| 168. | SOORI, G.S., et al., Phase II Study of Chemo-Biotherapy with Chlorambucil and Alpha Interferon in Patients with Non-Hodgkin's Lymphoma (NHL), Abstract #4032, Blood, 1998, pp. 240b, Vol. 92, No. 10 | |
| 169. | STADLER, W.M., et al., Multicenter Phase II Trial of Interleukin-2, Interferon- α , and 13-cis-Retinoic Acid in Patients With Metastatic Renal-Cell Carcinoma, Journal of Clinical Oncology, May 1998, pp.1820-1825, Vol. 16, No. 5 | |
| 170. | STRAUSS, G.M., et al., Multimodality Treatment of Stage IIIA Non-Small-Cell Lung Carcinoma: A critical Review of the Literature and Strategies for Future Research, Journal of Clinical Oncology, May, 1992, pp. 829-838, Vol. 10, No. 5 | |
| 171. | SUH, N., et al., Novel Triterpenoids Suppress Inducible Nitric Oxide Synthase (iNOS) and Inducible Cyclooxygenase (COX-2) in Mouse Macrophages ¹ , Cancer Research, Feb. 15, 1998, pp. 717-723, Vol. 58 | |
| 172. | TAKADA, Y., et al., Structures and functions of integrins, Jikken Igaku, 1996, pp. 2317-2322, Vol. 14 (17), English Abstract from SciFinder, Nov. 29, 2001, p. 3 | A |
| 173. | TEICHER, B.A., et al., Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Research and Treatment, 1995. pp. 227-236, Vol. 36 | |
| 174. | TEICHER, B.A., et al., TNP-470/Minocycline/Cytotoxic Therapy: A Systems Approach to Cancer Therapy, European Journal of Cancer, 1996, pp. 2461-2466, Vol. 32A, No. 14 | |
| 175. | THOMAS, C.A., et al., High-Dose Methotrexate (HD-MTX) Monotherapy in Patients with CNS Non-Hodgkin's Lymphoma, Blood, 1998, Abstract #4033, pp. 240b, Vol. 92, No. 10 | |


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)  | | | | Complete if Known | |
| | | | | Application Number | 09/857,994 |
| | | | | Filing Date | October 5, 2001 |
| | | | | Confirmation Number | Unknown |
| | | | | First Named Inventor | John P. McKearn et al. |
| | | | | Group Art Unit | 1646 |
| | | | | Examiner Name | Unknown |
| Sheet | 13 | of | 13 | Attorney Docket No. | PHA 4295 (3167/6Z) |

RECEIVED
 AUG 23 2003
 TECH CENTER 1600/1900

| | | | |
|--|------|---|--|
| | 176. | TOLSMAN, S.S., et al., Peptides Derived from Two Separate Domains of the Matrix Protein Thrombospondin-1 Have Anti-Angiogenic Activity, The Journal of Cell Biology, 1993, pp. 497-511, Vol. 122 | |
| | 177. | TOURANI, J.-M., et al., Outpatient Treatment With Subcutaneous Interleukin-2 and Interferon Alfa Administration in Combination With Fluorouracil in Patients With Metastatic Renal Cell Carcinoma: Results of a Sequential Nonrandomized Phase II Study, Journal of Clinical Oncology, July 1998, pp. 2505-2513, Vol. 16, No. 7 | |
| | 178. | TUSZYNSKI, G.P., et al., The role of thrombospondin-1 in tumor progression and angiogenesis, Bioessays, 1996, pp. 71-76, Vol. 18, No. 1 | |
| | 179. | VARNER, J.A., et al., Tumor Angiogenesis and the Role of Vascular Cell Integrin $\alpha v \beta 3$, Impt. Adv. Onc., 1996, pp. 69-87 | |
| | 180. | ZUCKER, S., Experimental Models to Identify Antimetastatic Drugs: Are We There Yet?, A Position Paper, Annals of the New York Academy of Science, June 1999, pp. 208-211, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.) | |
| | 181. | ZUCKER, S., et al., Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues, Clinical and Experimental Applications, Annals of the New York Academy of Science, June 1999, pp. 212-227, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.